◀ Back to NFKB1

LOX — NFKB1

Text-mined interactions from Literome

Bonizzi et al., Mol Cell Biol 1999 (Adenocarcinoma) : Stimulation of lymphoid cells with interleukin-1beta (IL-1beta) led to ROI production and NF-kappaB activation, which could both be blocked by antioxidants or FLAP inhibitors, confirming that 5-LOX was the source of ROIs and was required for NF-kappaB activation in these cells ... However, reintroduction of a functional 5-LOX system in these cells allowed ROI production and 5-LOX dependent NF-kappaB activation
Kandouz et al., Prostaglandins Other Lipid Mediat 2003 (Prostatic Neoplasms) : The enzymatic product of arachidonic acid metabolism, 12 ( S ) -HETE, mediates the activation of NF-kappaB by the 12-LOX ... Considering the known involvement of MAP kinase pathway in NF-kappaB activation and that of 12 ( S ) -HETE in MAP kinase pathway, 12-LOX present in prostate cancer tissues may contribute to the constitutive activation of NF-kappaB in prostate cancer cells
Jatana et al., Journal of neuroinflammation 2006 : BW-B 70C down-regulated 5-LOX and inhibited iNOS expression by preventing NF-kappaB activation
Bonizzi et al., J Immunol 1997 : This study thus indicates that the activation of NF-kappaB following IL-1beta treatment involves the activation of phospholipase A2 and 5-LOX and the production of reactive oxygen intermediates ( ROIs ) in lymphoid cells, while in epithelial cells, another pathway predominates and could involve the acid sphingomyelinase